Core Insights - GRI Bio, Inc. is advancing a pipeline of Natural Killer T (NKT) cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases [1][3] - The company will present its research on the inactivation of iNKT cells and its effects on fibroblast activation and fibrosis at the 2025 ATS International Conference [2] Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory, fibrotic, and autoimmune diseases [3] - The company's lead program, GRI-0621, is an inhibitor of iNKT cell activity, targeting idiopathic pulmonary fibrosis, a disease with significant unmet medical needs [3] - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its pipeline [3]

LA JOLLA, CA, April 02, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 1,388,888 shares of its common stock (or common stock equivalents in lieu thereof), Series E-1 warrants to purchase up to 1,388,888 shares of co ...

GRI Bio, Inc.’s (GRI) shares plummeted 36.9% on April 1 after the company announced the pricing of a public offering of stock of $5 million.Earlier in the day, the stock surged after the company reported positive interim safety results from its ongoing phase IIa study evaluating pipeline candidate GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF).Last month, the company received notice from The Nasdaq Stock Market LLC stating that it regained compliance with Nasdaq’s “minimum bid price rule. ...

LA JOLLA, CA, April 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of a public offering of an aggregate of 1,388,888 shares of its common stock (or common stock equivalents in lieu thereof), Series E-1 warrants to purchase up to 1,388,888 shares of common stock, short-term ...

The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated Interim biomarker data on track for Q2 2025 and topline results expected Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side- effects, limited patient compliance and no impact on survival LA J ...

The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated Interim biomarker data on track for Q2 2025 and topline results expected Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side- effects, limited patient compliance and no impact on survival LA J ...

Core Viewpoint - GRI Bio, Inc. is advancing its innovative pipeline of NKT cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases, with recent achievements in expanding its global patent estate [1][2]. Patent Developments - The company has been granted two global patents, enhancing its intellectual property portfolio and supporting its innovative pipeline of over 500 proprietary compounds [2][5]. - The patents include coverage for GRI-0803, a novel activator of human type 2 diverse NKT cells for treating autoimmune disorders, and methods for modulating NKT cells in inflammatory conditions [5]. Clinical Development - GRI Bio is advancing its lead program, GRI-0621, in a Phase 2a clinical trial for idiopathic pulmonary fibrosis (IPF), with interim data expected in Q2 2025 and topline results in Q3 2025 [2][3]. - The company’s therapies target NKT cells to interrupt disease progression and restore immune system balance, addressing significant unmet medical needs [3]. Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on transforming the treatment landscape for inflammatory, fibrotic, and autoimmune diseases through its unique approach to NKT cell modulation [3].

Financial Results Announcement - GRI Bio, Inc. announced its financial results for the year ended December 31, 2024, on March 17, 2025[5]. - A press release detailing the financial results was issued as Exhibit 99.1[7]. - The report does not include specific financial metrics or performance indicators in the provided content[6]. - No specific user data, future outlook, or guidance was provided in the available content[6]. Company Classification and Trading - The company is classified as an emerging growth company under the Securities Act of 1933[4]. - The common stock of GRI Bio, Inc. is traded on The Nasdaq Capital Market under the symbol GRI[3]. - The report indicates that the information is not deemed "filed" for purposes of the Securities Exchange Act of 1934[6]. Company Information - The company is headquartered in La Jolla, CA, with a principal executive office address at 2223 Avenida de la Playa, Suite 208[3]. - The Chief Financial Officer, Leanne Kelly, signed the report on behalf of GRI Bio, Inc.[10]. Product and Market Activity - There are no mentions of new products, technologies, market expansion, or acquisitions in the provided documents[6].

Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively Cash runway expected to fund operations into Q2 2025, including interim data readout from GRI-0621 LA JOLLA, CA, March 17, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, has reported its fi ...

Core Insights - GRI Bio, Inc. is advancing its lead program GRI-0621, a treatment for idiopathic pulmonary fibrosis (IPF), with interim data expected in Q2 2025 and topline data in Q3 2025 [1][2][11] - The company reported a net loss of $8.2 million for the fiscal year ended December 31, 2024, with research and development expenses increasing to $3.8 million [6][8] - GRI Bio's cash and cash equivalents as of December 31, 2024, were approximately $5.0 million, expected to fund operations into Q2 2025 [8] Company Overview - GRI Bio is a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases [1][12] - The lead program GRI-0621 is a small molecule RAR-βɣ dual agonist that inhibits human iNKT cell activity, showing promise in improving fibrosis and liver function in preliminary trials [4][12] - The company is also developing a pipeline of novel type 2 diverse NKT agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds [12] Financial Performance - Research and development expenses increased by $0.6 million from 2023 to 2024, primarily due to the registrational development program for GRI-0621 [6] - General and administrative expenses decreased by $3.7 million from 2023 to 2024, attributed to reduced fees related to a merger with Vallon Pharmaceuticals, Inc. [7] - The company believes its existing cash will be sufficient to fund operations through Q2 2025, including the interim data readout from GRI-0621 [8]